The GUIDE.MRD (Guiding multi-modal therapies against MRD by liquid biopsies) consortium partners met for the first face-to-face annual meeting hosted by Dr. Núria Malats at CNIO – Spanish National Cancer Research Centre, in Madrid, Spain, from 22-23 October 2023.

During the first day, the monthly Steering Committee meeting took place in presence, chaired by the Academic Coordinator, Universitätsklinikum Hamburg Eppendorf and the Project Leader, Bristol Myers Squibb, followed by a networking evening hosted by CNIO with fruitful discussions on the GUIDE.MRD project and most recent data from ESMO 2023.

The second day was opened with welcoming remarks from the Academic Coordinator and a presentation on the hosting partner CNIO. After that, the Work Package leaders Ellen Heitzer (Medical University Graz, Austria, WP2) and Claus Lindbjerg Andersen (Aarhus University Hospital, Denmark, WP3), as well as clinical study leaders Matthias Löhr (Karolinska Institute, Sweden, WP3) and Jeroen Hiltermann (University Medical Center Groningen, The Netherlands, WP3) presented the most recent data and progress of the project.

Over 40 participants from the 22 partners engaged in very productive discussions on the results reached by the consortium in the first six months, as well as some of the main challenges and opportunities. It was also noted how input from patients has been incorporated since this early phase of the project through our partners The Synergist, Digestive Cancers Europe (DiCE), Lung Cancer Europe (LuCE), and the project’s Patients Advisory Board, especially about the first three clinical trials.

Author:
Ana Martins